177Lu-HTK03170 is the therapeutic 177Lu-labeled analogue of 68Ga-HTK03149, itself based on the molecule HTK03041. These molecules are developed at BC Cancer, Vancouver, Canada as PSMA targeting drugs intended to be used in the therapy of late stage metastasized prostate cancer. A Phase I/II trial with the pair 68Ga-HTK03149/177Lu-HTK03170 has been initiated in December 2022 and is supposed to be completed by end of 2026.

Target/Mechanism: PSMA


Radiation Type: beta electrons (β)